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Abstract
Background: Sitagliptin, a highly selective dipeptidyl peptidase-4 inhibitor, is the first in a new class of oral
antihyperglycemic agents (AHAs) for the treatment of patients with type 2 diabetes. Type 2 diabetes is a life-long
disease requiring chronic treatment and management. Therefore, robust assessment of the long-term safety and
tolerability of newer therapeutic agents is of importance. The purpose of this analysis was to assess the safety and
tolerability of sitagliptin by pooling 12 large, double-blind, Phase IIb and III studies up to 2 years in duration.
Methods: This analysis included 6139 patients with type 2 diabetes receiving either sitagliptin 100 mg/day (N =
3415) or a comparator agent (placebo or an active comparator) (N = 2724; non-exposed group). The 12 studies
from which this pooled population was drawn represent the double-blind, randomized, Phase IIB and III studies
that included patients treated with the clinical dose of sitagliptin (100 mg/day) for at least 18 weeks up to 2 years
and that were available in a single safety database as of November 2007. These 12 studies assessed sitagliptin as
monotherapy, initial combination therapy with metformin, or add-on combination therapy with other oral AHAs
(metformin, pioglitazone, sulfonylurea, sulfonylurea + metformin, or metformin + rosiglitazone). Patients in the
non-exposed group were taking placebo, pioglitazone, metformin, sulfonylurea, sulfonylurea + metformin, or
metformin + rosiglitazone. This safety analysis used patient-level data from each study to evaluate clinical and
laboratory adverse experiences.
Results: For clinical adverse experiences, the incidence rates of adverse experiences overall, serious adverse
experiences, and discontinuations due to adverse experiences were similar in the sitagliptin and non-exposed
groups. The incidence rates of specific adverse experiences were also generally similar in the two groups, with
the exception of an increased incidence rate of hypoglycemia observed in the non-exposed group. The incidence
rates of drug-related adverse experiences overall and discontinuations due to drug-related adverse experiences
were higher in the non-exposed group, primarily due to the increased incidence rate of hypoglycemia in this
group. For cardiac- and ischemia-related adverse experiences (including serious events), there were no
meaningful between-group differences. No meaningful differences between groups in laboratory adverse
experiences, either summary measures or specific adverse experiences, were observed.
Conclusion: In patients with type 2 diabetes, sitagliptin 100 mg/day was well tolerated in clinical trials up to 2
years in duration.
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Background
Sitagliptin is an oral, once-daily and highly selective
dipeptidyl peptidase-4 (DPP-4) inhibitor for the treat-
ment of patients with type 2 diabetes [1]. Inhibition of
DPP-4 activity by sitagliptin enhances fasting and post-
prandial levels of the intact incretins, glucagon-like pep-
tide-1 (GLP-1) and glucose-dependent insulinotropic
polypeptide (GIP) [2]. These incretins play a role in glu-
cose homeostasis by increasing insulin release in response
to a meal; GLP-1 also decreases glucagon release. Both of
these effects are glucose-dependent [3]. In placebo-con-
trolled trials up to 30 weeks in duration, sitagliptin
improved fasting and postprandial glycemic control. Sit-
agliptin, as monotherapy or as add-on therapy to other
oral antihyperglycemic agents (AHAs), including met-
formin, a thiazolidinedione, and a sulfonylurea, has a tol-
erability profile generally similar to placebo [4-13],
although an increase in adverse experiences primarily due
to an increase in hypoglycemia was observed when sit-
agliptin was added to ongoing therapy with a sulfonylurea
[10]. Further, in a 52-week, active comparator-controlled
trial, the addition of sitagliptin to metformin demon-
strated similar efficacy, with a lower incidence rate of
hypoglycemia and weight loss versus weight gain, relative
to the addition of glipizide to metformin [14].
As type 2 diabetes is a chronic, progressive disease that
requires long-term treatment and management, the long-
term safety and tolerability of sitagliptin at the usual reg-
istered dose of 100 mg/day is of importance. In this
report, the safety and tolerability of sitagliptin 100 mg/
day were examined in a pooled analysis of patient-level
data from 12 double-blind, randomized, Phase IIb and III
studies up to 2 years in duration in patients with type 2
diabetes. This pooled analysis provides for a comparison
of the safety and tolerability profile of patients treated
with sitagliptin 100 mg/day relative to the safety and tol-
erability profile of patients who participated in these stud-
ies but were treated with other therapies (placebo or other
oral AHAs), with both groups receiving diet and exercise
counseling throughout the studies. The safety and tolera-
bility of dose-adjusted sitagliptin as assessed over 54
weeks in a special populations study of 91 patients with
moderate to severe and end-stage renal insufficiency have
been reported elsewhere [15].
Methods
The present analysis focused on the safety and tolerability
of the clinical dose of sitagliptin (100 mg/day) approved
for use in this broad population of patients with type 2
diabetes [16]. The 12 studies from which this pooled pop-
ulation was drawn represent the double-blind, rand-
omized, Phase IIB and III studies that included patients
treated with the clinical dose of sitagliptin (100 mg/day)
for at least 18 weeks up to 2 years and that were available
in a single safety database as of November 2007. In these
studies, patients received sitagliptin as monotherapy or in
combination with other oral AHAs, depending upon the
particular trial. Patients not receiving sitagliptin received a
range of treatments, including placebo, pioglitazone, met-
formin, sulfonylurea, sulfonylurea + metformin, or met-
formin + rosiglitazone. This comparison group, patients
not receiving sitagliptin, is referred to as the "non-
exposed" group. The pooling was conducted by including,
from each contributing study, parallel treatment groups of
patients with exposure to sitagliptin 100 mg/day (100 mg
q.d. [once daily] or 50 mg b.i.d. [twice daily]) that was
concurrent to exposure to other treatments (either pla-
cebo or active-comparator, Table 1) for generally similar
periods of time. Based upon data from a Phase IIb study
showing a similar safety and efficacy profile for sitagliptin
100 mg/day administered as either 100 mg q.d. or 50 mg
b.i.d. [8], data from these two treatment groups were
pooled for this analysis. There were 3 studies in which sit-
agliptin was administered as 50 mg b.i.d., either alone or
in combination with metformin: the 2 Phase IIb studies
[6,8], and the study of initial combination therapy with
sitagliptin and metformin that simulated the b.i.d. admin-
istration of a fixed-dose combination of sitagliptin and
metformin [12].
This safety analysis used patient-level data from each
study for the evaluation of clinical and laboratory adverse
experiences. Adverse experiences were encoded in these
studies using the MedDRA (Medical Dictionary for Regu-
latory Activities; version 10.0) system, a medically vali-
dated terminology database developed by the
International Conference on Harmonisation. Within this
dictionary, adverse event terms are grouped by type of
adverse experience (e.g., "Infections and Infestations" or
"Investigations") or by body system (e.g., "Gastrointesti-
nal [GI] Disorders" or "Cardiac Disorders"), with group-
ings referred to as "System Organ Classes" or SOCs. For
adverse experiences reported by SOC, a patient was
counted once if he/she experienced any adverse experi-
ences included within the SOC (e.g., a patient with the
separately reported adverse experiences of 'nausea' and
'abdominal pain' is included separately in the lines for
each specific adverse experience but counted only once in
the listing for the broader "GI Disorders" SOC, which
summarizes the proportions of patients who experienced
at least one GI adverse experience). Adverse experiences
were expressed as incidence rates (i.e., number of patients
with an event divided by total number of patients
exposed). Differences in incidence rates between treat-
ment groups and 95% confidence intervals (CI) were cal-
culated using Wilson's score method [17], and clinical
adverse experiences with between-treatment group differ-
ences in incidence rates for which the 95% CI excluded
zero were tabulated. To provide more detail on the overallBMC Endocrine Disorders 2008, 8:14 http://www.biomedcentral.com/1472-6823/8/14
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safety of sitagliptin, specific clinical and laboratory
adverse experiences reported for at least 1% of patients in
any group were summarized. Since drug-related and seri-
ous clinical adverse experiences are generally reported less
frequently, these events were summarized using lower cut
points (i.e., 0.5% and 0.2% of patients, respectively).
In most studies included in this analysis, glycemic rescue
therapy was to be implemented based upon protocol-
specified hyperglycemic criteria. The primary analysis in
this pooled safety population focused on the results
excluding data obtained from time points after a patient
initiated rescue therapy to avoid the confounding influ-
ence of the rescue therapy.
Table 1: Studies and treatment arms included in this pooled analysis
Study and Reference* Study Design Sitagliptin 100 mg/day 
Group
(N = 3415)
n Non-exposed Group
(N = 2724)
n
P010: twice-daily dose-range finding [6] 106-week active-controlled 
period
• Sitagliptin 50 mg b.i.d. 
switched to 100 mg q.d.
122 ￿ Glipizide 123
P014: once-daily dose-range finding [8] 12-week placebo-controlled 
period and 94-week active-
controlled period
￿ Sitagliptin 100 mg q.d. 110 ￿ Placebo (12 weeks) switched to metformin 
(94 weeks)
111
￿ Sitagliptin 50 mg b.i.d. 
switched to Sitagliptin 
100 mg q.d.
111
P019: placebo-controlled add-on to 
pioglitazone study [11]
24-week placebo-controlled 
period
￿ Sitagliptin 100 mg q.d. 
+ pioglitazone
175 ￿ Placebo + pioglitazone 178
P020: placebo-controlled add-on to 
metformin study [9]
24-week placebo-controlled 
period and 80-week active-
controlled period
￿ Sitagliptin 100 mg q.d. 
+ metformin
464 ￿ Placebo + metformin (24 weeks) switched 
to glipizide + metformin 
(80 weeks)
237
P021: placebo-controlled monotherapy 
study [4]
24-week placebo-controlled 
period
￿ Sitagliptin 100 mg q.d. 238 ￿ Placebo 253
P023: placebo-controlled 18-week placebo-controlled 
period and 36-week active-
controlled period
￿ Sitagliptin 100 mg q.d. 205 ￿ Placebo (18 weeks) switched to 
pioglitazone (36 weeks)
110
P024: active-comparator controlled 
add-on to metformin study [14]
104-week active-controlled 
period
￿ Sitagliptin 100 mg q.d. 
+ metformin
588 ￿ Glipizide + metformin 584
P035: placebo-controlled add-on to 
glimepiride, alone or in combination 
with metformin [10]
24-week placebo-controlled 
period and 30-week active-
controlled period
￿ Sitagliptin 100 mg q.d. 
+ glimepiride 
(± metformin)
222 ￿ Placebo + glimepiride (± metformin) (24 
weeks) switched to pioglitazone + 
glimepiride (± metformin) (30 weeks)
219
P036: placebo- and active-controlled 
study of initial combination use of 
metformin and sitagliptin[12]
24 week placebo-controlled 
period and 30-week active-
controlled period
￿ Sitagliptin 100 mg q.d. 179 ￿ Placebo (24 weeks) switched to metformin 
1000 mg
b.i.d. (30 weeks)
176
￿ Sitagliptin 50 mg
b.i.d./metformin 500 mg 
b.i.d.
190 ￿ Metformin 500 mg b.i.d. 182
￿ Sitagliptin 50 mg
b.i.d./metformin 1000 mg 
b.i.d.
182 ￿ Metformin 1000 mg b.i.d. 182
P040: placebo-controlled monotherapy 
study [39]
18-week placebo-controlled 
period
￿ Sitagliptin 100 mg q.d. 352 ￿ Placebo 178
P052: placebo-controlled add-on to 
metformin and rosiglitazone study [40]
18-week placebo-controlled 
period
￿ Sitagliptin 100 mg q.d. 
+ metformin and 
rosiglitazone
181 ￿ Placebo + metformin and rosiglitazone 97
P053: placebo-controlled add-on to 
metformin study [13]
30-week placebo-controlled 
period
￿ Sitagliptin 100 mg q.d. 
+ metformin
96 ￿ Placebo + metformin 94
*References are for the initial phases of the studies that had extension or continuations phases. Studies P019, P040, and P053 did not have continuation phases. 
For Studies P052, patients continued their sitagliptin or placebo treatment in the currently ongoing continuation phase.BMC Endocrine Disorders 2008, 8:14 http://www.biomedcentral.com/1472-6823/8/14
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To assess the robustness of the conclusions from the pri-
mary analysis, the results were also analyzed by including
data obtained from time points after a patient initiated
rescue therapy. An additional analysis, evaluating the
number of events per 100 patient-years in study (event
rates), was also performed.
Potential Mechanism-Based Adverse Experiences
Delayed gastric emptying associated with pharmacologic
levels of intact GLP-1 has been associated with increased
incidences of GI-related adverse experiences such as nau-
sea and vomiting [3]. Since sitagliptin increases intact
GLP-1 and GIP levels by 2- to 3-fold [2,18], certain GI
adverse experiences were pre-specified for statistical anal-
ysis (including diarrhea, nausea, vomiting and abdominal
pain [including upper and lower abdominal pain and
abdominal/stomach discomfort]) in the sitagliptin devel-
opment program. Further, since cases of pancreatitis have
been reported in association with treatment with a GLP-1
analogue [19,20], this GI adverse experience was also of
interest in this pooled analysis.
The DPP-4 enzyme (also referred to as the protein CD26)
is expressed on activated T cells, and, although the role of
DPP-4 enzyme activity in T cell function is not clear, it is
unlikely related to the co-stimulatory function of CD26
[21,22]. Animals genetically deficient in CD26 are healthy
and fertile without an evident increase in infections [23],
and immune function as well as lymph nodes, spleen, and
bone marrow in animals treated with a selective DPP-4
inhibitor appear normal [24,25]. Further, in vitro prolifer-
ation of human peripheral blood monocytes is unaffected
by selective DPP-4 inhibition [24]. Given the possibility
of immune alteration with DPP-4 inhibition, however,
adverse experiences in the "Infection and Infestation"
SOC were specifically reviewed in the present report.
Serious hypersensitivity reactions, including Stevens-
Johnson syndrome, have been reported with the use of sit-
agliptin in the postmarketing environment [16]. While
the causal relationship between sitagliptin and such
adverse experiences voluntarily reported from a popula-
tion of unknown size cannot be definitively established,
skin-related adverse experiences were examined in the
present pooled analysis. Skin-related findings are also of
interest, as preclinical administration of some DPP-4
inhibitors other than sitagliptin (e.g., vildagliptin and
PHX1149) [26,27] had been associated with dose-
dependent necrotic skin lesions when administered to
monkeys. These preclinical findings have not been
observed when sitagliptin was administered to monkeys
[28], and an increased incidence of skin findings consist-
ent with the preclinical lesions has not been reported in
patients in controlled clinical studies with DPP-4 inhibi-
tors, including studies with sitagliptin, vildagliptin,
alogliptin, and saxagliptin.
It has been theorized that DPP-4 inhibition could lead to
increased events of angioedema, particularly in patients
concomitantly treated with angiotensin-converting
enzyme (ACE) inhibitors (another class of agents with
peptidase activity) [29]. Therefore, a potential association
between ACE inhibitor use and the incidence of
angioedema-related events (see Appendix I for list of
events considered angioedema-related) was evaluated.
For this analysis, angioedema-related events were evalu-
ated for the periods with and without exposure to an ACE
inhibitor. Exposure to an ACE inhibitor was defined as the
total days of ACE inhibitor use during the double-blind
treatment period. Patients contributed to patient-years of
exposure to an ACE inhibitor for the actual period of time
that they were reported to have been taking an ACE inhib-
itor and to patient-years of non-exposure for the actual
period of time that they were reported not to have been
taking an ACE inhibitor. Data were expressed as event
rates for both incident angioedema-related events (all first
events of angioedema) and total angioedema-related
events (all events, including those occurring more than
once for the same patient) per 100 patient-years of expo-
sure.
Cardiovascular-related Adverse Experiences
Patients with type 2 diabetes are at increased risk for car-
diovascular morbidity and mortality [30]. Recently, there
has been increased focus on treatments for diabetes and
cardiovascular risk. Therefore, the between-group differ-
ences in incidence rates of cardiac (e.g., all cardiac-related
adverse experiences, including ischemic and non-
ischemic events) and ischemia-related adverse experiences
were evaluated in this pooled analysis. This analysis
presents adverse experience terms as reported by the
investigator; terms for ischemia-related events reported
for these studies are found in Appendix II. No formal
adjudication was performed.
Results
Patient Characteristics and Exposure
In this pooled analysis, there were 6139 patients overall,
with 3415 in the sitagliptin 100-mg group and 2724 in the
non-exposed group. At baseline, patients in the total
cohort had an average age of 55 years (range: 19 to 87
years), a mean duration of diabetes of 5.5 years, and a
mean A1C of 8.2%. Men comprised 55% of this cohort
and the racial/ethnic breakdown was 57.4% White, 16.2%
Asian, 15.2% Hispanic, 5.6% Black, and 5.6% "Other".
There were no meaningful differences between treatment
groups in these baseline characteristics or in the frequency
or type of other medical conditions or medications used.BMC Endocrine Disorders 2008, 8:14 http://www.biomedcentral.com/1472-6823/8/14
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The mean exposure to drug and total patient-years in
study were slightly greater in the sitagliptin group relative
to the non-exposed group: 307.3 dosing days (range = 1
to 792) relative to 293.6 dosing days (1 to 801), respec-
tively. In the sitagliptin group, 1343 patients were treated
for at least 1 year, with 356 of these patients treated for 2
years. The corresponding numbers of patients in the non-
exposed group were 981 and 290. The total duration of
observation in study was 2994 patient-years for the sit-
agliptin group relative to 2270 patient-years for the non-
exposed group. In these studies up to 2 years in duration,
the proportions of patients discontinuing treatment over-
all were 34.9% in the sitagliptin group and 39.5% in the
non-exposed group, with the reasons for discontinuations
generally similar between groups (Table 2).
Clinical Adverse Experiences in the Sitagliptin and Non-
Exposed Treatment Groups
The following sections report the results from the primary
safety analysis. The findings from the primary safety anal-
ysis (excluding data after glycemic rescue therapy) were
generally consistent with those that included data after
rescue therapy and with those examining the event rates
per 100 patient-years (data not shown).
Summary measures of the incidence rates of adverse expe-
riences overall, serious adverse experiences, and discon-
tinuations due to adverse experiences were similar in the
sitagliptin and non-exposed groups (Table 3). Drug-
related adverse experiences and discontinuations due to
drug-related adverse experiences were higher in non-
exposed patients, primarily due to hypoglycemia in sulfo-
nylurea-treated patients. In a few SOCs, there were small
differences in the incidence rates of adverse experiences
(Table 4). For the "Blood and Lymphatic System Disor-
ders" SOC, a slightly higher incidence rate of the adverse
experience of anemia in the sitagliptin group compared to
the non-exposed group (0.4% vs. 0.1%, respectively;
between-group difference [95% CI] = 0.3% [-0.0, 0.6])
accounted for a majority of the between-group difference.
The between-group difference in incidence rate in the
"Metabolism and Nutrition Disorders" SOC was prima-
rily due to a higher incidence rate of hypoglycemia in the
non-exposed group (10.9%) (primarily seen in sulfonylu-
rea-treated patients) relative to the sitagliptin group
(3.4%) (Table 5). For the "Investigations" SOC, 3 adverse
experiences (blood glucose increased, blood glucose
decreased, and weight increased) accounted for the higher
incidence rate in the non-exposed group relative to the sit-
agliptin group (Table 6).
The most commonly reported adverse experiences in
either group were hypoglycemia, upper respiratory tract
infection, and nasopharyngitis (Table 6). Of these events,
only nasopharyngitis occurred more frequently in the sit-
agliptin group, although the 95% CI around the between-
group difference included 0 (between-group difference
[95% CI] = 1.2% [-0.1, 2.4]. For specific clinical adverse
experiences reported more frequently in a treatment
group and for which the 95% CI around the between-
group difference excluded 0, there were 7 specific adverse
experiences that were higher in the sitagliptin group and
11 that were higher in the non-exposed group (Table 5).
The largest between-group difference (7.4%) was
observed for the adverse experience of hypoglycemia,
which occurred at a higher incidence rate in the non-
exposed group; otherwise the between-group differences
in incidence rates were small (< 1%; Table 5). In the devel-
opment program for sitagliptin, an episode of hypoglyc-
emia was defined as an episode with symptoms of
hypoglycemia assessed by the investigator as a clinical
adverse experience of hypoglycemia based upon review of
the patient's hypoglycemia log. Incidence rates of
hypoglycemia were based upon all reports of hypoglyc-
emia; a concurrent fingerstick glucose was not required.
The incidence rates of hypoglycemia were driven largely
by the use of a sulfonylurea as a comparator agent or as
background therapy. Of the 296 patients in the non-
exposed group having at least one episode of hypoglyc-
emia, 239 (81%) had an episode while treated with a sul-
fonylurea. For the patients not treated with a sulfonylurea,
the incidence rates for hypoglycemia were 2.6% (n/N: 87/
3298) and 2.3% (50/2428) in the sitagliptin and non-
exposed groups, respectively. The incidence rates of spe-
cific clinical adverse experiences occurring in at least 1%
of patients in either group are listed in Table 6.
The incidence rate of drug-related clinical adverse experi-
ences overall was higher in the non-exposed group
(17.7%) compared with the sitagliptin group (12.9%),
primarily due to reports of hypoglycemia and blood glu-
cose decreased. Drug-related adverse experiences that
occurred at an incidence rate of at least 0.5% in either
group are listed in Table 7.
The incidence rate of serious clinical adverse experiences
overall was approximately 7% in each treatment group. A
review of specific serious clinical adverse experiences irre-
spective of the relationship to study drug that occurred at
an incidence rate of at least 0.2% did not reveal any nota-
ble between-group differences (Table 8).
Potentially Mechanism-Based Adverse Experiences
The incidence rates of GI adverse experiences did not
meaningfully differ between groups (Tables 4, 5, 6). For
the pre-specified GI adverse experiences (diarrhea, nau-
sea, vomiting and abdominal pain [including upper and
lower abdominal pain and abdominal/stomach discom-
fort]), the incidence rates were generally similar between
groups (Table 6). In the sitagliptin and non-exposedBMC Endocrine Disorders 2008, 8:14 http://www.biomedcentral.com/1472-6823/8/14
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groups, the incidence rates of pancreatitis (0.1% and 0%,
respectively), acute pancreatitis (0% and 0.1%, respec-
tively) and chronic pancreatitis (0.1% and 0%, respec-
tively) were low and not meaningfully different between
the groups.
The overall incidence rates and intensity of adverse expe-
riences of infection were similar in the two treatment
groups, as, in general, were the frequencies and particular
types of infections reported (Table 4 and Table 6). Further,
the incidence rates of adverse experiences of infection that
were reported as serious or that led to discontinuation
were similar between groups. In addition, there was no
evident increase in the frequency of specific types of infec-
tions suggestive of immune suppression (e.g., herpes
zoster) between groups. As noted above, the incidence
rate of the adverse experience of nasopharyngitis was
slightly higher in the sitagliptin group, but in both treat-
ment groups the events were generally mild in intensity
and similar in duration, generally occurring as isolated
events and after similar time periods following study ini-
tiation, and did not recur more frequently in patients in
the sitagliptin group relative to those in the non-exposed
group.
The overall incidence rate of adverse experiences in the
"Skin and Subcutaneous Tissue Disorders" SOC was not
meaningfully different between groups (Table 4). Two
adverse experiences (acne and contact dermatitis [with
approximately half of the events being "poison ivy/oak"])
were reported more frequently in the sitagliptin group
compared with the non-exposed group, whereas hyperk-
eratosis was reported more frequently in the non-exposed
group (Table 5). Rash was the only skin-related adverse
experience reported by at least 1% of the patients in either
group (Table 6), with an incidence rate of 1.0% in the sit-
Table 2: Overall disposition of the 6139 randomized patients in the sitagliptin and non-exposed groups
Sitagliptin 100 mg Non-Exposed
RANDOMIZED, N 3415 2724
n (%) n (%)
DISCONTINUED* 1191 (34.9) 1076 (39.5)
Reason for discontinuation
Clinical adverse experience 119 (3.5) 113 (4.1)
Laboratory adverse experience 38 (1.1) 22 (0.8)
Lack of efficacy† 458 (13.4) 381 (14.0)
Patient discontinued for other 152 (4.5) 176 (6.5)
Patient moved 33 (1.0) 19 (0.7)
Patient withdrew consent 186 (5.4) 203 (7.4)
Protocol specified discontinuation criteria 48 (1.4) 44 (1.6)
Protocol deviation 58 (1.7) 50 (1.8)
Lost to follow-up 97 (2.8) 65 (2.4)
Site terminated 2 (0.1) 3 (0.1)
*To provide a complete accounting of the 6139 randomized patients, this table includes data from patients after they received glycemic rescue 
therapy, whereas the primary safety analysis focuses on results excluding data after patients received rescue therapy. These numbers include 
patients discontinued over periods of up to 2 years, including those patients who underwent glycemic rescue during the placebo-controlled phase 
and were ineligible in some studies to enter into the continuation phase.
†Includes patients not meeting the progressively stricter, protocol-specified, glycemic rescue criteria and/or not meeting the investigator's 
expectations of glycemic improvement.BMC Endocrine Disorders 2008, 8:14 http://www.biomedcentral.com/1472-6823/8/14
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agliptin group and 0.9% in the non-exposed group. No
adverse experiences of Stevens-Johnson syndrome were
reported in patients in the clinical trials that were pooled
for this report; one event of erythema multiforme was
reported for a patient in the non-exposed group. No
adverse experiences consistent with the lesions observed
during the preclinical development of some other (non-
sitagliptin) DPP-4 inhibitors were reported.
For the analysis of angioedema-related events and the
relationship of these events to concurrent treatment with
ACE inhibitors, approximately 33% of patients were on
an ACE inhibitor at baseline and approximately 36% were
on an ACE inhibitor at any time during the studies (for a
total of 1,023 and 779 patient-years on an ACE inhibitor
for the sitagliptin and non-exposed groups, respectively).
Among the 6139 patients included in this pooled analysis,
there were 54 incident angioedema-related events, 16 of
which occurred in patients concurrently taking an ACE
inhibitor. The number of incident angioedema-related
events per 100 patient-years while a patient was on an
ACE inhibitor was the same (0.9) in both groups. The
total numbers of angioedema-related events per 100
patient-years while a patient was on an ACE inhibitor
were also similar in the sitagliptin (1.1) and non-exposed
(0.9) groups. For patients not on an ACE inhibitor, the
numbers of incident angioedema-related events per 100
patient-years were 1.1 in the sitagliptin group and 1.3 in
the non-exposed group.
Cardiovascular-related Adverse Experiences
The incidence rates of overall and serious adverse experi-
ences in the "Cardiac Disorders" SOC were similar
between groups (Table 4), with the overall incidence rates
of serious adverse experiences in this SOC being 1.2% in
the sitagliptin group and 1.5% in the non-exposed group
(between-group difference [95% CI] = -0.3% [-1.0, 0.3]).
In an analysis in which ischemia-related adverse experi-
ences overall were assessed, the incidence rates were 2.0%
in the sitagliptin group and 2.3% in the non-exposed
group (between-group difference [95% CI] = -0.2% [-1.0,
0.5]). For the serious ischemia-related adverse experi-
ences, the incidence rates were 1.1% in the sitagliptin
group and 1.5% in the non-exposed group (between-
group difference [95% CI] = -0.4% [-1.0, 0.2]). There were
3 patients (0.09%) in the sitagliptin group (2 with
ischemic stroke and 1 with myocardial infarction) with a
fatal ischemic event compared with 7 patients (0.26%) in
the non-exposed group (4 with myocardial infarction, 1
with myocardial ischemia, and 2 with sudden cardiac
death).
Laboratory Adverse Experiences in the Sitagliptin and 
Non-Exposed Treatment Groups
Summary measures of the incidence rates of laboratory
adverse experiences overall, serious laboratory adverse
experiences, and discontinuations due to laboratory
adverse experiences were similar in the two groups (Table
9). There were no meaningful between-group differences
Table 3: Clinical adverse experience summary
Sitagliptin 100 mg
n (%)
(N = 3415)
Non-Exposed
n (%)
(N = 2724)
Difference in Sitagliptin
and Non-Exposed
% (95% CI)*
With one or more adverse experiences 2150 (63.0) 1711 (62.8) 0.1 (-2.3, 2.6)
With drug-related adverse experiences† 440 (12.9) 483 (17.7) -4.8 (-6.7, -3.0)
With serious adverse experiences 230 (6.7) 184 (6.8) -0.0 (-1.3, 1.2)
With serious drug-related adverse experiences† 8 (0.2) 8 (0.3) -0.1 (-0.4, 0.2)
Who died 11 (0.3) 16 (0.6) -0.3 (-0.7, 0.1)
Discontinued due to adverse experiences 106 (3.1) 101 (3.7) -0.6 (-1.5, 0.3)
Discontinued due to drug-related adverse experiences 30 (0.9) 40 (1.5) -0.6 (-1.2, -0.1)
Discontinued due to serious adverse experiences 51 (1.5) 47 (1.7) -0.2 (-0.9, 0.4)
Discontinued due to serious drug-related adverse experiences 4 (0.1) 4 (0.1) -0.0 (-0.3, 0.2)
CI = confidence interval
*Positive differences indicate that the incidence rate for the sitagliptin group is higher than the incidence rate for the non-exposed group. "0.0" and 
"-0.0" represent rounding for values that are slightly greater and slightly less than zero, respectively.
†Determined by the investigator to be possibly, probably, or definitely drug-related.BMC Endocrine Disorders 2008, 8:14 http://www.biomedcentral.com/1472-6823/8/14
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Table 4: Summary of clinical adverse experiences by system organ class
System Organ Class Sitagliptin 100 mg
n (%)
(N = 3415)
Non-Exposed
n (%)
(N = 2724)
Difference between Sitagliptin
and Non-Exposed
% (95% CI)*
Blood and Lymphatic System Disorders 33 (1.0) 11 (0.3) 0.6 (0.1, 1.0)
Cardiac Disorders 136 (4.0) 105 (3.9) 0.1 (-0.9, 1.1)
Congenital, Familial, and Genetic Disorders 7 (0.2) 4 (0.1) 0.1 (-0.2, 0.3)
Ear And Labyrinth Disorders 50 (1.5) 53 (1.9) -0.5 (-1.2, 0.2)
Endocrine Disorders 9 (0.3) 15 (0.6) -0.3 (-0.7, 0.0)
Eye Disorders 140 (4.1) 112 (4.1) -0.0 (-1.0, 1.0)
Gastrointestinal Disorders 659 (19.3) 493 (18.1) 1.2 (-0.8, 3.1)
General Disorders And Administration Site Conditions 259 (7.6) 212 (7.8) -0.2 (-1.6, 1.1)
Hepatobiliary Disorders 44 (1.3) 27 (1.0) 0.3 (-0.3, 0.8)
Immune System Disorders 32 (0.9) 25 (0.9) 0.0 (-0.5, 0.5)
Infections And Infestations 1179 (34.5) 897 (32.9) 1.6 (-0.8, 4.0)
Injury, Poisoning And Procedural Complications 290 (8.5) 222 (8.1) 0.3 (-1.1, 1.7)
Investigations 143 (4.2) 145 (5.3) -1.1 (-2.2, -0.1)
Metabolism And Nutrition Disorders 219 (6.4) 373 (13.7) -7.3 (-8.8, -5.8)
Musculoskeletal And Connective Tissue Disorders 576 (16.9) 434 (15.9) 0.9 (-0.9, 2.8)
Neoplasms Benign, Malignant And Unspecified† 76 (2.2) 44 (1.6) 0.6 (-0.1, 1.3)
Nervous System Disorders 433 (12.7) 344 (12.6) 0.1 (-1.6, 1.7)
Pregnancy, Puerperium, and Perinatal Conditions 1 (0.0) 2 (0.1) -0.0 (-0.2, 0.1)
Psychiatric Disorders 143 (4.2) 121 (4.4) -0.3 (-1.3, 0.8)
Renal And Urinary Disorders 99 (2.9) 74 (2.7) 0.2 (-0.7, 1.0)
Reproductive System And Breast Disorders 90 (2.6) 84 (3.1) -0.4 (-1.3, 0.4)
Respiratory, Thoracic And Mediastinal Disorders 279 (8.2) 208 (7.6) 0.5 (-0.8, 1.9)
Skin And Subcutaneous Tissue Disorders 248 (7.3) 169 (6.2) 1.1 (-0.2, 2.3)
Social Circumstances 2 (0.1) 1 (0.0) 0.0 (-0.2, 0.2)
Surgical and Medical Procedures 3 (0.1) 1 (0.0) 0.1 (-0.1, 0.2)
Vascular Disorders 181 (5.3) 141 (5.2) 0.1 (-1.0, 1.2)
CI = confidence interval
*Positive differences indicate that the incidence rate for the sitagliptin group is higher than the incidence rate for the non-exposed group. "0.0" and "-0.0" 
represent rounding for values that are slightly greater and slightly less than zero, respectively.
†For malignant tumors n (%): 31 (0.9%) in the sitagliptin group and 26 (1.0%) in the non-exposed group.BMC Endocrine Disorders 2008, 8:14 http://www.biomedcentral.com/1472-6823/8/14
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Table 5: Clinical adverse experiences for which the 95% confidence intervals around the difference in incidence rate exclude 0
Adverse Experience Sitagliptin 100 mg
n (%)
(N = 3415)
Non-Exposed
n (%)
(N = 2724)
Difference in Sitagliptin
and Non-Exposed,
% (95% CI)*
Sitagliptin > Non-exposed
Atrial fibrillation† 18 (0.5) 5 (0.2) 0.3 (0.0, 0.7)
Asthenia 19 (0.6) 6 (0.2) 0.3 (0.0, 0.7)
Chest discomfort 9 (0.3) 1 (0.0) 0.2 (0.0, 0.5)
Tooth abscess‡ 27 (0.8) 10 (0.4) 0.4 (0.0, 0.8)
Osteoarthritis 58 (1.7) 24 (0.9) 0.8 (0.2, 1.4)
Acne 7 (0.2) 0 (0) 0.2 (0.0, 0.4)
Dermatitis Contact 24 (0.7) 7 (0.3) 0.4 (0.1, 0.8)
Non-exposed > Sitagliptin
Bradycardia 0 (0) 4 (0.1) -0.1 (-0.4, -0.0)
Goiter 1 (0.0) 6 (0.2) -0.2 (-0.5, -0.0)
Change in bowel habit 0 (0) 4 (0.1) -0.1 (-0.4, -0.0)
Blood glucose decreased 13 (0.4) 28 (1.0) -0.6 (-1.1, -0.2)
Blood glucose increased 42 (1.2) 51 (1.9) -0.6 (-1.3, -0.0)
Weight increased 12 (0.4) 20 (0.7) -0.4 (-0.8, -0.0)
Hypoglycemia 117 (3.4) 296 (10.9) -7.4 (-8.8, -6.1)
Sinus headache 3 (0.1) 12 (0.4) -0.4 (-0.7, -0.1)
Prostatitis 3 (0.1) 9 (0.3) -0.2 (-0.5, -0.0)
Balanitis 0 (0) 4 (0.1) -0.1 (-0.4, -0.0)
Hyperkeratosis 0 (0) 8 (0.3) -0.3 (-0.6, -0.1)
CI = confidence interval
*Positive differences indicate that the incidence rate for the sitagliptin group is higher than the incidence rate for the non-exposed group. "0.0" and 
"-0.0" represent rounding for values that are slightly greater and slightly less than zero, respectively.
†When atrial fibrillation and atrial flutter were combined, the incidence rates were 0.5% and 0.3% for the sitagliptin and non-exposed groups, 
respectively (between-group difference [95% CI] = 0.3 [-0.1, 0.6]).
‡When tooth abscess and tooth infection were combined, the incidence rates were 1.3% and 0.9% for the sitagliptin and non-exposed groups, 
respectively (between-group difference [95% CI] = 0.4 [-0.1, 1.0]).BMC Endocrine Disorders 2008, 8:14 http://www.biomedcentral.com/1472-6823/8/14
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Table 6: Clinical adverse experiences occurring at an incidence rate ≥1% in any group
Adverse Experience Sitagliptin 100 mg
n (%)
(N = 3415)
Non-Exposed
n (%)
(N = 2724)
Difference between Sitagliptin
and Non-Exposed,
% (95% CI)*
Vertigo 24 (0.7) 27 (1.0) -0.3 (-0.8, 0.2)
Abdominal Pain 39 (1.1) 33 (1.2) -0.1 (-0.6, 0.5)
Abdominal Pain Upper 59 (1.7) 33 (1.2) 0.5 (-0.1, 1.1)
Constipation 79 (2.3) 47 (1.7) 0.6 (-0.1, 1.3)
Diarrhea 170 (5.0) 144 (5.3) -0.3 (-1.4, 0.8)
Dyspepsia 70 (2.0) 40 (1.5) 0.6 (-0.1, 1.2)
Gastritis 36 (1.1) 30 (1.1) -0.0 (-0.6, 0.5)
Nausea 85 (2.5) 70 (2.6) -0.1 (-0.9, 0.7)
Toothache 35 (1.0) 33 (1.2) -0.2 (-0.8, 0.3)
Vomiting 51 (1.5) 34 (1.2) 0.2 (-0.4, 0.8)
Fatigue 56 (1.6) 53 (1.9) -0.3 (-1.0, 0.4)
Peripheral Edema 62 (1.8) 54 (2.0) -0.2 (-0.9, 0.5)
Bronchitis 135 (4.0) 83 (3.0) 0.9 (-0.0, 1.8)
Cellulitis 28 (0.8) 26 (1.0) -0.1 (-0.6, 0.3)
Gastroenteritis 68 (2.0) 48 (1.8) 0.2 (-0.5, 0.9)
Gastroenteritis Viral 29 (0.8) 27 (1.0) -0.1 (-0.7, 0.3)
Influenza 145 (4.2) 127 (4.7) -0.4 (-1.5, 0.6)
Nasopharyngitis 244 (7.1) 162 (5.9) 1.2 (-0.1, 2.4)
Pharyngitis 52 (1.5) 35 (1.3) 0.2 (-0.4, 0.8)
Sinusitis 80 (2.3) 60 (2.2) 0.1 (-0.6, 0.9)
Upper Respiratory Tract Infection 265 (7.8) 228 (8.4) -0.6 (-2.0, 0.8)
Urinary Tract Infection 134 (3.9) 100 (3.7) 0.3 (-0.7, 1.2)
Viral Infection 36 (1.1) 21 (0.8) 0.3 (-0.2, 0.8)
Blood Glucose Decreased 13 (0.4) 28 (1.0) -0.6 (-1.1, -0.2)
Blood Glucose Increased 42 (1.2) 51 (1.9) -0.6 (-1.3, -0.0)
Hyperglycemia 34 (1.0) 39 (1.4) -0.4 (-1.0, 0.1)
Hypoglycemia† 117 (3.4) 296 (10.9) -7.4 (-8.8, -6.1)BMC Endocrine Disorders 2008, 8:14 http://www.biomedcentral.com/1472-6823/8/14
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in the number of laboratory adverse experiences reported
with an incidence rate of at least 1% (Table 10). For
hepatic transaminases, the proportions of patients in the
sitagliptin and non-exposed groups with their last meas-
urement (obtained either at time of discontinuation or at
the final scheduled study visit) of ALT > 3 times the upper
limit of normal (3xULN) were 0.7% and 0.8%, respec-
tively; the proportions with last AST measurement >
3xULN were 0.4% and 0.2%, respectively. The number of
patients meeting the definition of Hy's Rule (i.e., an ALT
and/or AST measurement > 3xULN and a bilirubin >
2xULN) at any time during the study was 2 in the sitaglip-
tin group (with both cases resolving while continuing
treatment; 1 patient had suspected concurrent bacteremia
and a history of steatohepatitis, and the other had ele-
vated ALT/AST and alkaline phosphatase prior to rand-
omization) and 1 in the non-exposed group (in a patient
with concurrent diagnosis of a liver abscess).
Discussion
In this pooled analysis of clinical studies up to 2 years in
duration, treatment with sitagliptin 100 mg/day was
found to be well tolerated, with generally similar inci-
dence rates of clinical and laboratory adverse experiences
in patients treated with sitagliptin relative to those not
exposed to sitagliptin. There was a higher incidence rate of
drug-related adverse experiences in the non-exposed
group, primarily due to the increased incidence rate of
hypoglycemia in studies in which a sulfonylurea was used
as an active comparator.
Arthralgia 113 (3.3) 92 (3.4) -0.1 (-1.0, 0.8)
Back Pain 142 (4.2) 108 (4.0) 0.2 (-0.8, 1.2)
Muscle Spasms 38 (1.1) 35 (1.3) -0.2 (-0.8, 0.4)
Musculoskeletal Pain 54 (1.6) 40 (1.5) 0.1 (-0.5, 0.7)
Myalgia 38 (1.1) 29 (1.1) 0.0 (-0.5, 0.6)
Neck Pain 23 (0.7) 26 (1.0) -0.3 (-0.8, 0.2)
Osteoarthritis 58 (1.7) 24 (0.9) 0.8 (0.2, 1.4)
Pain in Extremity 84 (2.5) 53 (1.9) 0.5 (-0.2, 1.2)
Dizziness 86 (2.5) 63 (2.3) 0.2 (-0.6, 1.0)
Headache 169 (4.9) 129 (4.7) 0.2 (-0.9, 1.3)
Hypoesthesia 24 (0.7) 31 (1.1) -0.4 (-1.0, 0.0)
Anxiety 32 (0.9) 27 (1.0) -0.1 (-0.6, 0.4)
Depression 40 (1.2) 29 (1.1) 0.1 (-0.4, 0.6)
Insomnia 44 (1.3) 35 (1.3) 0.0 (-0.6, 0.6)
Cough 88 (2.6) 73 (2.7) -0.1 (-0.9, 0.7)
Pharyngolaryngeal Pain 44 (1.3) 34 (1.2) 0.0 (-0.5, 0.6)
Rash 35 (1.0) 24 (0.9) 0.1 (-0.4, 0.6)
Hypertension 110 (3.2) 89 (3.3) -0.0 (-1.0, 0.8)
CI = confidence interval; *Positive differences indicate that the incidence rate for the sitagliptin group is higher than the incidence rate for the non-
exposed group. "0.0" and "-0.0" represent rounding for values that are slightly greater and slightly less than zero, respectively.
†Includes studies in which a sulfonylurea was an active comparator or a background agent.
Table 6: Clinical adverse experiences occurring at an incidence rate ≥1% in any group (Continued)BMC Endocrine Disorders 2008, 8:14 http://www.biomedcentral.com/1472-6823/8/14
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In previously reported placebo-controlled trials with sit-
agliptin as monotherapy, as initial combination therapy
with metformin, or as an add-on therapy to agents not
associated with hypoglycemia (e.g., metformin, a thiazo-
lidinedione), the incidence rate of hypoglycemia with sit-
agliptin was low and similar to placebo [4-9,11-13]. This
low incidence rate of hypoglycemia observed with sit-
agliptin is consistent with its glucose-dependent mecha-
nism of action [31]. When sitagliptin was added to
ongoing therapy with a sulfonylurea, there was an
Table 7: Clinical adverse experiences considered to be related to study drug† that occurred at an incidence rate of ≥0.5% in any group
Sitagliptin 100 mg
n (%)
(N = 3415)
Non-Exposed
n (%)
(N = 2724)
Difference between Sitagliptin
and Non-Exposed
% (95% CI)*
Abdominal Pain Upper 18 (0.5) 11 (0.4) 0.1 (-0.2, 0.5)
Constipation 25 (0.7) 13 (0.5) 0.3 (-0.2, 0.7)
Diarrhea 42 (1.2) 45 (1.7) -0.4 (-1.1, 0.2)
Dyspepsia 19 (0.6) 13 (0.5) 0.1 (-0.3, 0.4)
Nausea 33 (1.0) 31 (1.1) -0.2 (-0.7, 0.3)
Fatigue 19 (0.6) 20 (0.7) -0.2 (-0.6, 0.2)
Peripheral Edema 11 (0.3) 16 (0.6) -0.3 (-0.7, 0.1)
Blood Glucose 6 (0.2) 16 (0.6) -0.4 (-0.8, -0.1)
Decreased
Hypoglycemia‡ 87 (2.5) 203 (7.5) -4.9 (-6.1, -3.8)
Dizziness 17 (0.5) 13 (0.5) 0.0 (-0.4, 0.4)
Headache 37 (1.1) 29 (1.1) 0.0 (-0.5, 0.5)
CI = confidence interval
*Positive differences indicate that the incidence rate for the sitagliptin group is higher than the incidence rate for the non-exposed group. "0.0" and 
"-0.0" represent rounding for values that are slightly greater and slightly less than zero, respectively.
†Determined by the investigator to be possibly, probably, or definitely drug-related.
‡Includes studies in which a sulfonylurea was an active comparator or a background agent.
Table 8: Serious clinical adverse experiences irrespective of relationship to study drug that occurred at an incidence rate of ≥0.2% in 
any group
Sitagliptin 100 mg
n (%)
(N = 3415)
Non-Exposed
n (%)
(N = 2724)
Difference between Sitagliptin
and Non-Exposed
% (95% CI)*
Coronary Artery Disease 5 (0.1) 7 (0.3) -0.1 (-0.4, 0.1)
Myocardial Infarction 4 (0.1) 5 (0.2) -0.1(-0.3, 0.1)
Non-cardiac Chest Pain 4 (0.1) 9 (0.3) -0.2 (-0.5, 0.0)
Cholelithiasis 6 (0.2) 2 (0.1) 0.1 (-0.1, 0.3)
Pneumonia 4 (0.1) 5 (0.2) -0.1 (-0.3, 0.1)
CI = confidence interval
*Positive differences indicate that the incidence rate for the sitagliptin group is higher than the incidence rate for the non-exposed group. "0.0" and 
"-0.0" represent rounding for values that are slightly greater and slightly less than zero, respectively.BMC Endocrine Disorders 2008, 8:14 http://www.biomedcentral.com/1472-6823/8/14
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Table 9: Laboratory adverse experience summary
Sitagliptin 100 mg
n (%)
(N = 3375)
Non-Exposed
n (%)
(N = 2680)
Difference in Sitagliptin
and Non-Exposed
% (95% CI)*
With one or more adverse experiences 378 (11.2) 293 (10.9) 0.3 (-1.3, 1.8)
With drug-related adverse experiences† 102 (3.0) 78 (2.9) 0.1 (-0.8, 1.0)
With serious adverse experiences 3 (0.1) 0 (0) 0.1 (-0.1, 0.3)
With serious drug-related adverse experiences† 0 (0) 0 (0) 0.0 (-0.1, 0.1)
Who died 0 (0) 0 (0) 0.0 (-0.1, 0.1)
Discontinued due to adverse experiences 36 (1.1) 18 (0.7) 0.4 (-0.1, 0.9)
Discontinued due to drug-related adverse experiences 16 (0.5) 9 (0.3) 0.1 (-0.2, 0.5)
Discontinued due to serious adverse experiences 0 (0) 0 (0) 0.0 (-0.1, 0.1)
Discontinued due to serious drug-related adverse experiences 0 (0) 0 (0) 0.0 (-0.1, 0.1)
CI = confidence interval
*Positive differences indicate that the incidence rate for the sitagliptin group is higher than the incidence rate for the non-exposed group. "0.0" and 
"-0.0" represent rounding for values that are slightly greater and slightly less than zero, respectively.
†Determined by the investigator to be possibly, probably, or definitely drug-related.
Table 10: Laboratory adverse experiences occurring at an incidence rate of ≥1% in any group
Adverse Experience Sitagliptin 100 mg
n/N (%)
Non-Exposed
n/N (%)
Difference between Sitagliptin
and Non-Exposed,
% (95% CI)*
Alanine Aminotransferase Increased 51/3365 (1.5) 37/2672 (1.4) 0.1 (-0.5, 0.7)
Aspartate Aminotransferase Increased 35/3365 (1.0) 26/2672 (1.0) 0.1 (-0.5, 0.6)
Blood Uric Acid Increased 37/3364 (1.1) 22/2672 (0.8) 0.3 (-0.2, 0.8)
Creatine Phosphokinase Increased 22/819 (2.7) 11/619 (1.8) 0.9 (-0.7, 2.5)
Creatinine Clearance Estimation Decreased 31/3243 (1.0) 14/2551 (0.5) 0.4 (-0.1, 0.9)
Fasting Blood Glucose Increased 52/3370 (1.5) 63/2675 (2.4) -0.8 (-1.6, 0.1)
Low Density Lipoprotein Increased 5/185 (2.7) 2/169 (1.2) 1.5 (-1.9, 5.1)
Protein Urine Present 19/1541 (1.2) 7/1209 (0.6) 0.7 (-0.1, 1.4)
Urine Microalbumin Present 2/228 (0.9) 9/251 (3.6) -2.7 (-5.9, 0.1)
CI = confidence interval
Data are number of patients with a laboratory adverse experience/number of patients with laboratory measurement expressed as a percentage (n/
N [%]).
*Positive differences indicate that the incidence rate for the sitagliptin group is higher than the incidence rate for the non-exposed group. "0.0" and 
"-0.0" represent rounding for values that are slightly greater and slightly less than zero, respectively.BMC Endocrine Disorders 2008, 8:14 http://www.biomedcentral.com/1472-6823/8/14
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increase in the incidence rate of hypoglycemia compared
to the addition of placebo [10]. This phenomenon has
been observed in trials of other AHAs (e.g., metformin,
thiazolidinediones, and exenatide), which themselves are
not associated with hypoglycemia, when they are added
to a sulfonylurea agent [32-34]. In the present pooled
analysis, the aggregate incidence rate of hypoglycemia in
the sitagliptin group reflects the incidence rates across
many studies with various treatment paradigms, includ-
ing the study in which sitagliptin was added on to a sulfo-
nylurea.
GI side effects are observed with different AHAs, including
metformin and α-glucosidase inhibitors [35]. GLP-1 ana-
logues such as exenatide produce levels of GLP-1 activity
that are far in excess of physiologic levels and are associ-
ated with an increased incidence of nausea and vomiting
[3]. In this pooled analysis, the incidence rates of GI
adverse experiences, including nausea and vomiting, were
similar in the sitagliptin and the non-exposed groups.
This was not unexpected because the increased levels of
active GLP-1 and GIP observed with the use of DPP-4
inhibitors remain within a physiologic range [3]. Consist-
ent with these findings, when sitagliptin was co-adminis-
tered with metformin, the GI adverse experience profile of
the combination was similar to that of metformin alone
[9,12,13].
Inhibition of DPP-4 with a highly selective compound has
been shown not to alter measures of immune function in
animals  in vivo and in human immune cells in vitro
[24,25]. Moreover, mice completely lacking the CD26
molecule are healthy and fertile [23,36]. Consistent with
these observations, in the present pooled analysis there
were no meaningful differences observed between treat-
ment groups in the incidence rate, severity, and type of
infections. Amori et al. suggested an increased risk for cer-
tain infections (nasopharyngitis and urinary tract infec-
tion) with DPP-4 inhibitors (including sitagliptin and
vildagliptin) in a recent meta-analysis of efficacy and
safety of incretin-based therapies [37]. In the current anal-
ysis, only a small numeric increase in the incidence rate of
nasopharyngitis in the sitagliptin group was observed,
while the incidence rates of urinary tract infections were
similar in the two groups. Differences between the current
findings and those of Amori et al. may be due to several
factors, including the larger cohort of patients followed
for a longer duration in the present analysis of clinical tri-
als of sitagliptin. Further, the present analysis included all
available clinical trial safety data for the specified popula-
tions while the Amori meta-analysis could have only
included selected adverse experiences meeting different
criteria for inclusion in the source manuscripts referenced.
Researchers have suggested that reduced DPP-4 enzyme
activity and DPP-4 enzyme deficiency increase ACE inhib-
itor-induced angioedema in rats and potentially humans
[29,38]. These authors hypothesized that the concomitant
use of DPP-4 inhibitors and ACE inhibitors could increase
the risk of angioedema-related adverse experiences. The
clinical experience reported in the present analysis does
not support this hypothetical association. Moreover, a
higher rate of angioedema-related events in sitagliptin-
treated patients, regardless of ACE inhibitor use, was not
observed in the present analysis. Hypersensitivity reac-
tions with administration of sitagliptin (including those
considered as severe) have been reported based upon
postmarketing surveillance. In the current pooled analysis
of events reported from controlled clinical trials, hyper-
sensitivity events occurred with similar incidence rates in
patients taking sitagliptin relative to the non-exposed
group.
Although the studies in this analysis were not cardiovas-
cular outcome trials, but rather trials assessing the overall
safety and efficacy of sitagliptin 100 mg/day, there were
no meaningful differences between groups in the inci-
dence rates of cardiac-related or ischemia-related adverse
experiences.
Conclusion
In patients with type 2 diabetes, sitagliptin 100 mg/day
was well tolerated as monotherapy, as initial combination
therapy, and as add-on therapy in double-blind, rand-
omized clinical studies up to 2 years in duration. The
safety of sitagliptin continues to be monitored in ongoing
clinical studies and through postmarketing surveillance.
Appendix 1. List of terms* used in the 
angioedema-related adverse events analysis
Eye disorders system organ class (SOC)
Eye edema, Eye swelling, Eyelid edema
Immune system disorders SOC
Anaphylactic reaction, Angioedema, Drug hypersensitiv-
ity, Hypersensitivity
Skin and subcutaneous tissue disorders SOC
Face edema, Periorbital edema, Swelling face, Urticaria,
Urticaria generalized
*From the adverse experiences reported in this pooled
analysis, these reported terms were identified as
angioedema-related.
Appendix 2. List of terms* used in the ischemia-
related adverse events analysis
Vascular disorders SOCBMC Endocrine Disorders 2008, 8:14 http://www.biomedcentral.com/1472-6823/8/14
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Aortic arteriosclerosis, Aortic stenosis, Arteriosclerosis,
Arteriosclerosis obliterans, Extremity necrosis, Iliac artery
stenosis, Intermittent claudication, Leriche syndrome,
Peripheral arterial occlusive disease, Peripheral ischemia
Nervous system disorders SOC
Carotid artery disease, Carotid artery stenosis, Cerebellar
infarction, Cerebral infarction, Cerebrovascular accident,
Ischemic stroke, Lacunar infarction, Thalamic infarction,
Transient ischemic attack, Vertebrobasilar insufficiency
Cardiac disorders SOC**
Acute coronary syndrome, Acute myocardial infarction,
Angina pectoris, Angina unstable, Arteriosclerosis coro-
nary artery, Coronary artery disease, Coronary artery
insufficiency, Coronary artery occlusion, Coronary artery
stenosis, Ischemic cardiomyopathy, Myocardial infarc-
tion, Myocardial ischemia, Silent myocardial infarction,
Ventricular tachycardia
General disorders and administration site conditions
SOC
Sudden cardiac death
*From the adverse experiences reported in this pooled
analysis, these reported terms were identified as ischemia-
related.
**One patient in the non-exposed group with sepsis and
multi-organ failure with cause of death reported as 'car-
dio-respiratory arrest' was not included in the ischemia-
related analyses.
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